Scholarlink

Background <p>In recent years, the incidence of cancer has been on the rise worldwide due to environmental pollution, poor lifestyle habits, and increasing medical diagnoses. In China, the incidence and mortality of lung cancer both rank first among malignant tumors. In the process of cancer diagnosis and treatment, patients with lung cancer undergoing chemotherapy experience a serious symptom burden. Inadequate symptom management will aggravate the physical and mental pain of patients and even delay or interrupt the treatment of the disease. Therefore, it is urgent to provide symptom management programs for medical staff and patients with lung cancer undergoing chemotherapy.</p> Objective <p>To construct the central symptom cluster management program for patients with lung cancer undergoing chemotherapy (CSCMP).</p> Methods <p>Under the guidance of Symptom Management Theory (SMT), the draft program was formed in December 2023 through the clinical expert meeting based on the best evidence summary, and the final program was formed after two rounds of Delphi with 17 experts between December 2023 and March 2024. Descriptive statistics and consistency tests (Kendall’s W) were used to analyze the data.</p> Results <p>The final program consists of 12 items in 7 different dimensions. The 7 dimensions are intervention symptom, intervention method, intervention time, intervention content, intervention personnel, intervention place, and intervention form. The 12 items include intervention training, focus assessment, health guidance, diet nursing, psychological nursing, exercise intervention, Traditional Chinese Medicine (TCM) intervention, energy-saving skills, life nursing, environmental nursing, sleep hygiene, and follow-up. In both rounds of Delphi, the recovery rate (RR) was 100%, the expert authority coefficient (Cr) was 0.888, the coefficient of variation (CV) was 0.130–0.280 and 0.110–0.197, respectively, the Kendall’s W was 0.467 and 0.523, respectively, and <i>P</i> &lt; 0.05.</p> Conclusion <p>CSCMP established in this study is scientific and credible, has clinical operability, and can guide medical staff and patients with lung cancer undergoing chemotherapy to carry out symptom management in complex clinical environments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Construction of the central symptom cluster management program for patients with lung cancer undergoing chemotherapy: a Delphi study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月14日

查看全文
  • Le Zhang,
  • Yuanyuan Luo,
  • Dongmei Mao,
  • Benxiang Zhu,
  • Zhihui Yang,
  • Cui Cui,
  • Jingxia Miao,
  • Lili Zhang

摘要

Background

In recent years, the incidence of cancer has been on the rise worldwide due to environmental pollution, poor lifestyle habits, and increasing medical diagnoses. In China, the incidence and mortality of lung cancer both rank first among malignant tumors. In the process of cancer diagnosis and treatment, patients with lung cancer undergoing chemotherapy experience a serious symptom burden. Inadequate symptom management will aggravate the physical and mental pain of patients and even delay or interrupt the treatment of the disease. Therefore, it is urgent to provide symptom management programs for medical staff and patients with lung cancer undergoing chemotherapy.

Objective

To construct the central symptom cluster management program for patients with lung cancer undergoing chemotherapy (CSCMP).

Methods

Under the guidance of Symptom Management Theory (SMT), the draft program was formed in December 2023 through the clinical expert meeting based on the best evidence summary, and the final program was formed after two rounds of Delphi with 17 experts between December 2023 and March 2024. Descriptive statistics and consistency tests (Kendall’s W) were used to analyze the data.

Results

The final program consists of 12 items in 7 different dimensions. The 7 dimensions are intervention symptom, intervention method, intervention time, intervention content, intervention personnel, intervention place, and intervention form. The 12 items include intervention training, focus assessment, health guidance, diet nursing, psychological nursing, exercise intervention, Traditional Chinese Medicine (TCM) intervention, energy-saving skills, life nursing, environmental nursing, sleep hygiene, and follow-up. In both rounds of Delphi, the recovery rate (RR) was 100%, the expert authority coefficient (Cr) was 0.888, the coefficient of variation (CV) was 0.130–0.280 and 0.110–0.197, respectively, the Kendall’s W was 0.467 and 0.523, respectively, and P < 0.05.

Conclusion

CSCMP established in this study is scientific and credible, has clinical operability, and can guide medical staff and patients with lung cancer undergoing chemotherapy to carry out symptom management in complex clinical environments.